These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27894787)

  • 1. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.
    Kajiwara M; Tanaka A; Kawasaki T; Nakao K; Sakamoto T; Toyoda S; Inoue T; Koga N; Node K
    J Cardiol; 2017 Mar; 69(3):511-517. PubMed ID: 27894787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
    Davies MJ; Bain SC; Atkin SL; Rossing P; Scott D; Shamkhalova MS; Bosch-Traberg H; Syrén A; Umpierrez GE
    Diabetes Care; 2016 Feb; 39(2):222-30. PubMed ID: 26681713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Nozue T; Yamada M; Tsunoda T; Katoh H; Ito S; Iwaki T; Michishita I
    Heart Vessels; 2016 Aug; 31(8):1239-46. PubMed ID: 26293570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
    Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.
    Osonoi T; Saito M; Tamasawa A; Ishida H; Tsujino D; Nishimura R; Utsunomiya K
    PLoS One; 2014; 9(12):e113468. PubMed ID: 25526642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
    Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
    Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.
    Chen WR; Tian F; Chen YD; Wang J; Yang JJ; Wang ZF; Da Wang J; Ning QX
    Int J Cardiol; 2016 Apr; 208():109-14. PubMed ID: 26849684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).
    Htike ZZ; Yates T; Brady EM; Webb D; Gray LJ; Swarbrick D; McCann GP; Khunti K; Davies MJ
    Cardiovasc Diabetol; 2016 Jul; 15(1):102. PubMed ID: 27440110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.
    Chen WR; Chen YD; Tian F; Yang N; Cheng LQ; Hu SY; Wang J; Yang JJ; Wang SF; Gu XF
    Circ Cardiovasc Imaging; 2016 Dec; 9(12):. PubMed ID: 27940956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
    Yamamoto S; Hayashi T; Ohara M; Goto S; Sato J; Nagaike H; Fukase A; Sato N; Hiromura M; Tomoyasu M; Nakanishi N; Lee S; Osamura A; Yamamoto T; Fukui T; Hirano T
    Diabetes Res Clin Pract; 2018 Jun; 140():339-346. PubMed ID: 29588170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.
    Hiramatsu T; Ozeki A; Asai K; Saka M; Hobo A; Furuta S
    Ther Apher Dial; 2015 Dec; 19(6):598-605. PubMed ID: 26556397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
    Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
    Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.
    Li Q; Wu C; Sun S; Yang L; Li Y; Niu Y; Zhang L; Li W; Yu Y
    J Diabetes; 2024 Jul; 16(7):e13517. PubMed ID: 38173120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
    Liu Y; Jiang X; Chen X
    Lipids Health Dis; 2017 Dec; 16(1):227. PubMed ID: 29197387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.